CN116870038A - Post-natal powder of lactobacillus plantarum J26 and application of post-natal powder in aspect of cholesterol reduction - Google Patents
Post-natal powder of lactobacillus plantarum J26 and application of post-natal powder in aspect of cholesterol reduction Download PDFInfo
- Publication number
- CN116870038A CN116870038A CN202310916587.XA CN202310916587A CN116870038A CN 116870038 A CN116870038 A CN 116870038A CN 202310916587 A CN202310916587 A CN 202310916587A CN 116870038 A CN116870038 A CN 116870038A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus plantarum
- cholesterol
- post
- powder
- metapowder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 52
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 51
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 51
- 239000000843 powder Substances 0.000 title claims abstract description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract description 74
- 235000012000 cholesterol Nutrition 0.000 title abstract description 34
- 230000009467 reduction Effects 0.000 title abstract description 9
- 150000002632 lipids Chemical class 0.000 claims abstract description 18
- 150000007524 organic acids Chemical class 0.000 claims abstract description 7
- 150000004831 organic oxygen compounds Chemical class 0.000 claims abstract description 7
- 238000000855 fermentation Methods 0.000 claims description 20
- 230000004151 fermentation Effects 0.000 claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- 239000008103 glucose Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000001963 growth medium Substances 0.000 claims description 11
- 235000020183 skimmed milk Nutrition 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 239000002054 inoculum Substances 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 238000005273 aeration Methods 0.000 claims description 3
- 239000012526 feed medium Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002572 peristaltic effect Effects 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- OSCCDBFHNMXNME-WDCZJNDASA-N (2s,3s,4r)-2-amino-4-hydroxy-3-methylpentanoic acid Chemical compound C[C@@H](O)[C@@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-WDCZJNDASA-N 0.000 claims description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 2
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 2
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 108010085443 Anserine Proteins 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 2
- 239000011703 D-panthenol Substances 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- 235000004866 D-panthenol Nutrition 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- 239000008777 Glycerylphosphorylcholine Substances 0.000 claims description 2
- SLRNWACWRVGMKD-UHFFFAOYSA-N L-anserine Natural products CN1C=NC(CC(NC(=O)CCN)C(O)=O)=C1 SLRNWACWRVGMKD-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 2
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 2
- 241000210053 Potentilla elegans Species 0.000 claims description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- MBWUSSKCCUMJHO-ZGXDEBHDSA-N Solamargine Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O MBWUSSKCCUMJHO-ZGXDEBHDSA-N 0.000 claims description 2
- MBWUSSKCCUMJHO-DVDUUUGDSA-N Solamargine Natural products O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@@]6(O[C@H]5C4)NC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](C)O1 MBWUSSKCCUMJHO-DVDUUUGDSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001009 acetylcarnitine Drugs 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- MYYIAHXIVFADCU-QMMMGPOBSA-N anserine Chemical compound CN1C=NC=C1C[C@H](NC(=O)CC[NH3+])C([O-])=O MYYIAHXIVFADCU-QMMMGPOBSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000017663 capsaicin Nutrition 0.000 claims description 2
- 229960002504 capsaicin Drugs 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-N choline alfoscerate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-N 0.000 claims description 2
- 229960003949 dexpanthenol Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 claims description 2
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 2
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 claims description 2
- LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 claims description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- 229940096998 ursolic acid Drugs 0.000 claims description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 2
- LGQKSQQRKHFMLI-WSNPFVOISA-N xylobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)C(O)OC1 LGQKSQQRKHFMLI-WSNPFVOISA-N 0.000 claims description 2
- YGEHCIVVZVBCLE-FSYGUOKUSA-N 3alpha-galactobiose Chemical compound OC[C@@H](O)[C@H](O)[C@@H]([C@@H](O)C=O)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YGEHCIVVZVBCLE-FSYGUOKUSA-N 0.000 claims 1
- QIGJYVCQYDKYDW-VXSGSMIHSA-N alpha-D-Manp-(1->3)-D-Manp Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@H]1O QIGJYVCQYDKYDW-VXSGSMIHSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 30
- 210000004185 liver Anatomy 0.000 abstract description 15
- 210000002966 serum Anatomy 0.000 abstract description 15
- 235000005911 diet Nutrition 0.000 abstract description 12
- 230000037213 diet Effects 0.000 abstract description 12
- 108010023302 HDL Cholesterol Proteins 0.000 abstract description 11
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 11
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 8
- 210000003608 fece Anatomy 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000004584 weight gain Effects 0.000 abstract description 6
- 235000019786 weight gain Nutrition 0.000 abstract description 6
- 230000004596 appetite loss Effects 0.000 abstract description 2
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 239000003613 bile acid Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 6
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 6
- 229960005370 atorvastatin Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 206010054949 Metaplasia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000015689 metaplastic ossification Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000260 hypercholesteremic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940009291 bifidobacterium longum Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 229920000080 bile acid sequestrant Polymers 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000033227 intestinal cholesterol absorption Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a post-generated powder of lactobacillus plantarum J26 and application thereof in cholesterol reduction, belonging to the technical field of microbial preparations, wherein the post-generated powder of lactobacillus plantarum J26 comprises 24.89 weight percent of lipid and lipid molecules, 18.10 weight percent of organic acid and derivative, 12.85 weight percent of organic oxygen compound and the balance of lactobacillus plantarum J26 inactivated thallus, and the concentration of the lactobacillus plantarum J26 inactivated thallus is 10 8 Cells of Lactobacillus plantarum J26/g. The metapowder has the effect of relieving hypercholesterolemia, and is specifically characterized in that: significantly alleviating weight gain and appetite loss in high-fat high-cholesterol diet mice; cholesterol lowering is lowering TC, TG, LDL-C levels in serum or liver, raising HDL-C levels; significantly improves the total cholesterol and total cholesterol in the feces of high-fat high-cholesterol diet miceBile acid levels.
Description
Technical Field
The invention relates to a metapowder of lactobacillus plantarum J26 and application thereof in cholesterol reduction, belonging to the technical field of microbial preparations.
Background
Hypercholesterolemia is an important risk factor for atherosclerosis, coronary heart disease, stroke and other diseases. There is evidence that every 1% increase in serum cholesterol levels increases the incidence of cardiovascular disease by 2-3%. World Health Organization (WHO) predicts that by 2030, mortality from cardiovascular related diseases will reach 40%, accounting for approximately 2360 ten thousand of deaths worldwide.
The etiology of hypercholesterolemia includes hereditary, eating, bad lifestyle, drugs, and other diseases. The main characteristics are that the concentration of Total Cholesterol (TC), low Density Lipoprotein (LDL) and Triglyceride (TG) in serum is high, and the concentration of High Density Lipoprotein (HDL) is low. With the increasing level of living, the need to treat hypercholesterolemia has become more urgent.
Currently the primary cholesterol lowering regimen involves exercise, diet control and the use of lipid-regulating drugs such as statins, inhibitors of intestinal cholesterol absorption, bile acid sequestrants and other drugs. However, the long-term administration of the medicine can cause gastrointestinal reactions such as nausea, vomiting, abdominal distension, constipation and the like, and increase the risk of diabetes. Therefore, there is a need to develop natural non-pharmaceutical cholesterol-lowering functional products.
Disclosure of Invention
The invention aims to provide a metapowder of lactobacillus plantarum J26 and application thereof in preparation of cholesterol-lowering drugs.
In order to solve the technical problems, the invention adopts the following technical scheme:
lactobacillus plantarumLactobacillus plantarum) The application of the metapowder of J26 in preparing cholesterol-lowering medicines.
The metapowder is obtained by drying and inactivating lactobacillus plantarum J26.
The method for high-density fermentation before the inactivation of the lactobacillus plantarum J26 comprises the following steps: inoculating lactobacillus plantarum J26 strain into 4L skim milk powder culture medium with an inoculum size of 5%, and performing high-density fermentation for 18h, wherein the liquid fermentation environment is as follows: the temperature is 37 ℃, the humidity is 70%, the pH is 5.5, the aeration rate is 1.5vvm, and the power of the stirrer is 1.5kwh/m 3 The method comprises the steps of carrying out a first treatment on the surface of the The glucose concentration in the feed medium is 750g/L, the glucose concentration in the culture medium fed to the skim milk powder in 10h, 12h and 14h is 30g/L, the glucose concentration in the culture medium fed to the skim milk powder in 16h and 18h is 40g/L, and the viable count of the obtained fermentation liquor reaches 3.23 multiplied by 10 11 cfu/mL。
And (3) carrying out spray drying on the obtained fermentation broth under the conditions of needle passing frequency of 8Hz, peristaltic speed of 5rmp and air inlet of 180 ℃ to obtain the metapowder of the lactobacillus plantarum J26.
The metapowder of the lactobacillus plantarum J26 comprises 24.89 weight percent of lipid and lipid molecules, 18.10 weight percent of organic acid and derivative, 12.85 weight percent of organic oxygen compound and the balance of lactobacillus plantarum J26 inactivated thallus, wherein the concentration of the lactobacillus plantarum J26 inactivated thallus is 10 8 Cells of Lactobacillus plantarum J26/g.
The lipid and lipid molecules include one or more of ursolic acid, acetylcarnitine, D-panthenol, glycerophosphorylcholine, phosphatidylethanolamine, linolenic acid, linoleic acid, solamargine and capsaicin.
The organic acids and derivatives include one or more of 4-hydroxyisoleucine, arginine, fucosyllactose-N-hexasaccharide, pantothenic acid and anserine.
The organic oxygen compound comprises one or more of 1, 4-d-xylobiose, 3.alpha. -galactobiose, 3.alpha. -mannobiose, 3' -sialyllactose, glucosamine sulfate, galacto-N-disaccharide, lactose, maltotetraose, melezitose and raffinose.
The dosage forms of the medicine comprise granules, capsules, tablets, pills or oral liquid.
The metapowder of the invention is applied to the preparation of medicines for reducing or assisting in reducing cholesterol.
The invention relates to an application of metapowder in preparing health care products for assisting in reducing cholesterol.
Cholesterol lowering is a lowering of TC, TG, LDL-C levels in serum or liver, increasing HDL-C levels.
Cholesterol is reduced in order to increase fecal total cholesterol and total bile acid levels.
Cholesterol lowering is the reduction of weight gain and appetite increase.
The invention has the following beneficial effects:
the invention provides a post-generated element powder of lactobacillus plantarum J26 and application thereof in cholesterol reduction, wherein the post-generated element powder has the effect of relieving hypercholesterolemia, and is specifically characterized in that:
(1) Significantly alleviating weight gain and appetite loss in high-fat high-cholesterol diet mice;
(2) Significantly reducing the serum TC, TG, LDL-C level of high-fat high-cholesterol diet mice and improving the HDL-C level;
(3) Significantly reducing the liver TC, TG, LDL-C, AST, ALT level of a high-fat high-cholesterol diet mouse and improving the HDL-C level;
(4) Significantly improving the fecal total cholesterol and total bile acid levels of high-fat high-cholesterol diet mice;
therefore, lactobacillus plantarum is [ ]Lactobacillus plantarum) The metapowder prepared by J26 has great application prospect in preparing products of diseases related to hypercholesteremia.
Drawings
FIG. 1 shows the number of viable bacteria of the cells at different concentrations of glucose and culture times;
FIG. 2 is a comparison of weight gain, food intake and water intake of different groups of mice, wherein A is the weight gain of the different groups of mice after the end of the 14 th week experiment, B is the food intake of the different groups of mice during the 5 week treatment period, and C is the water intake of the different groups of mice during the 5 week treatment period; compared to HCD group, p <0.05, p <0.01, p <0.001, p <0.0001;
FIG. 3 shows comparison of serum biochemical indicators of different groups of mice; compared to HCD group, p <0.05, p <0.01, p <0.001, p <0.0001;
FIG. 4 is a comparison of liver biochemical indicators of different groups of mice; compared to HCD group, p <0.05, p <0.01, p <0.001, p <0.0001;
FIG. 5 is a comparison of total bile acid and total cholesterol levels in the feces of different groups of mice; compared to HCD groups, p <0.05, p <0.01, p <0.001, and p <0.0001.
Detailed Description
The invention will be further described with reference to the accompanying drawings.
In the invention, lactobacillus plantarum J26 is lactobacillus plantarum NDC75017, and the inventor purchases the lactobacillus plantarum through a strain collection center. The classification of Lactobacillus plantarum NDC75017 is named Lactobacillus plantarumLactobacillus plantarumThe strain is preserved in China general microbiological culture Collection center (CGMCC), beijing, and has a preservation date of 2011, 11 and 08, and a preservation number of CGMCC NO.5448; lactobacillus plantarum J26 is abbreviated asLactobacillus plantarumJ26、L. plantarum J26, LJ26 or J26.
Step one, lactobacillus plantarumLactobacillus plantarum) J26 preparation of metapowder
Preparing a skim milk powder culture medium: the components are prepared according to the weight percentage: 0.25% of maltose, 0.02% of sodium chloride, 0.8% of sodium acetate, 2-3% of peptone, 2-3% of beef extract, 2-3% of yeast extract, 8% of glucose, 0.35% of diammonium citrate, 0.15% of dipotassium hydrogen phosphate, 0.08% of magnesium sulfate, 0.03% of manganese sulfate, 0.03% of ferrous sulfate and the balance of skimmed milk powder. The above formulation was mixed with water (1:10, m/v) and autoclaved to prepare a skim milk powder medium.
The method for high-density fermentation comprises the following steps: plant milkThe bacillus J26 strain is inoculated in 4L skim milk powder culture medium with an inoculum size of 5 percent for high-density fermentation, and the liquid fermentation environment is as follows: the temperature is 37 ℃, the humidity is 70%, the pH is 5.5, the aeration rate is 1.5vvm, and the power of the stirrer is 1.5kwh/m 3 . The feed medium was 750g/L glucose. In connection with the results of FIG. 1, the feeding strategy was optimized to feed to a medium glucose concentration of 30g/L at 10h, 12h and 14h and 40g/L at 16h and 18 h. Under the optimized feeding strategy, the viable count of the obtained fermentation liquor reaches 3.23 multiplied by 10 11 cfu/mL, before optimization (lactobacillus plantarum J26 strain is inoculated in 4L of skim milk powder culture medium with an inoculum size of 5 percent, high-density fermentation is carried out, fermentation is carried out for 18 hours at 37 ℃, the liquid fermentation environment is the same as above, residual glucose in fermentation liquid at different time points is measured by using a glucose measuring kit, the feeding amount is determined, the feeding culture medium is 750g/L glucose, and the viable count of thallus is 3.15X10 when the glucose concentration of the culture medium is 40g/L after 10 hours, 12 hours, 14 hours, 16 hours and 18 hours 10 The cfu/mL thallus concentration is improved by 9.3 times.
Drying and inactivating method: and (3) spray drying the obtained fermentation broth under the conditions of needle passing frequency of 8Hz, peristaltic speed of 5rmp and air inlet of 180 ℃ to obtain the lactobacillus plantarum J26 metapowder (the inactivation rate is more than 99.99%).
The post-production powder of Lactobacillus plantarum J26 has a concentration of 10 8 Cells of Lactobacillus plantarum J26/g.
Step two, metabolites in J26 metameal
Taking 20mg of the lactobacillus plantarum J26 metapowder obtained in the step one, adding 0.5mL of precooled methanol/acetonitrile/water solution (2:2:1, v/v) at 4 ℃, mixing by vortex, carrying out low-temperature ultrasonic treatment at 4 ℃ for 30min, standing at-20 ℃ for 10min, centrifuging at 14000g at 4 ℃ for 20min, taking supernatant, drying in vacuum, adding 100 mu L of acetonitrile water solution (acetonitrile: water=1:1, v/v) for redissolution during mass spectrometry, carrying out vortex, centrifuging at 14000g at 4 ℃ for 15min, and taking supernatant for sample injection analysis. After the sample is separated by an Agilent 1290 information LC ultra-high performance liquid chromatography (UHPLC), a Triple TOF 6600 mass spectrometer (AB SCIEX) is used for mass spectrometry, and electrospray ionization (ESI) positive ion mode and negative ion mode are respectively used for detection. And firstly carrying out metabolite structure identification and data pretreatment on the extracted data, then carrying out experimental data quality evaluation, and finally carrying out data analysis. The ratio of lipid and lipid molecules in the lactobacillus plantarum J26 metameal is 24.89 percent, the ratio of organic acid and derivative is 18.10 percent, and the ratio of organic oxygen compound is 12.85 percent. The ratio of lipid and lipid molecules in lactobacillus plantarum J26 viable bacteria (prepared by a high-density fermentation process before optimization) is 21.16%, the ratio of organic acid and derivative is 13.25%, and the ratio of organic oxygen compound is 12.35%.
Effect of Lactobacillus plantarum J26 metaplasia powder on cholesterol reduction in high-fat high-cholesterol diet mice
The C57BL/6J mice referred to in the examples below were purchased from Beijing Vietnam Liwa.
1. Mouse modeling and grouping
80 male C57BL/6J mice (6 weeks old, weight 20-22 g) were placed at room temperature (22.+ -. 2 ℃) for 12h light/12 h dark period. After one week of adaptation, mice were randomly assigned to two groups: normal diet (ND group, n=10) and high fat high cholesterol diet (HCD, n=70) for 8 weeks. Mice fed HCD were then randomized into seven groups (n=10): (1) HCD group; (2) group L-J26P, lavage 200mg/kg body weight of mice; (3) group M-J26P, gavage 400mg/kg mouse body weight; (4) H-J26P group, gavage 800mg/kg mouse body weight; (5) Group J26, gavage 0.2mL Lactobacillus plantarum J26 (1X 10) 8 cfu/mL); (6) group of Atorvastatin, lavage 10mg/kg body weight of mice; (7) BB536 group, lavage 0.2mL commercial cholesterol lowering probiotic preparation bifidobacterium longum BB536 (1X 10) 8 cfu/mL). Mice in ND and HCD groups were orally given 0.2mL of sterile Phosphate Buffered Saline (PBS).
The experiment was performed for 14 weeks: after mice were acclimatized for one week, the blank group was fed with maintenance feed (energy ratio: 23.07% protein, 11.85% fat, 65.08% carbohydrate), the remaining group was fed with high fat high cholesterol feed (maintenance feed +15% lard +20% sucrose +1.2% cholesterol +0.2% sodium cholate), the mice serum biochemical index was measured every week, modeling was successful at the end of week 9, and from week 10, each of the metagroups was perfused with the corresponding metapowder, lactobacillus plantarum J26 lyophilized powder, drug atorvastatin, and commercial cholesterol lowering probiotic formulation bifidobacterium BB536 (dissolved in normal saline at the corresponding dose) at an amount of 0.2 mL/day, and the blank group and model group were perfused with the same amount of PBS solution as the control until the end of the experiment. All groups were free drinking and ingestion. The experimental animals were grouped as shown in table 1 below.
Table 1 experimental animal groups
2. Data monitoring
Mice morphology was observed. The body weight, food intake, water intake of the mice were recorded.
And (5) collecting blood and tissues of the mice. Blood was taken after the end of the experiment and mice were sacrificed. The liver was dissected and rapidly removed and rinsed in ice-cold physiological saline. The blood samples were centrifuged at 3000g for 10min at 4℃and serum was collected and stored at-80 ℃.
And (5) measuring blood lipid indexes. TG (triglyceride), TC (total cholesterol), HDL-C (high density lipoprotein cholesterol) and LDL-C (low density lipoprotein cholesterol) in blood lipid were measured by using the kit.
Measurement of relevant indicators in the liver. Part of liver tissue is mixed with 0.1mmol/L phosphate buffer solution according to the mass ratio of 1:10, homogenizing with a homogenizer, centrifuging for 10min at 10000g, collecting supernatant, and determining the contents of TG (triglyceride), TC (total cholesterol), HDL-C (high density lipoprotein cholesterol), LDL-C (low density lipoprotein cholesterol), ALT (glutamic pyruvic transaminase) and AST (glutamic oxaloacetic transaminase) according to the procedures of the kit.
Measurement of total bile acid and total cholesterol in feces. The assay was performed using an enzyme-linked immunosorbent assay (ELISA).
3. Experimental results
3.1 Mouse morphology
As shown in fig. 2, compared with the model group HCD, the medium and high dose metapowder groups, the viable bacteria control group, the drug control group and the commercial product control group all significantly inhibited the weight gain of the high-fat high-cholesterol diet mice after five weeks of administration, and the effect of the high dose lactobacillus plantarum J26 metapowder administration was most obvious, and was inferior to that of the atorvastatin drug treatment group. The intermediate and high dose Lactobacillus plantarum J26 metameal groups remarkably relieve the appetite reduction of mice caused by high-fat and high-cholesterol diet.
3.2 Mouse blood fat index
Serum TC, TG, LDL-C, HDL-C levels are critical for health monitoring of hypercholesterolemic patients. As can be seen from fig. 3, the biochemical index related to lipid metabolism was improved in the serum of mice after 5 weeks in the other treatment group compared with the HCD group. Serum TC levels in the H-J26P group were reduced by 28.82% and were next to atorvastatin drug treatment (32.29%). Serum TG levels were also significantly reduced in all treatment groups, 38.33% after H-J26P treatment. In vivo, when there is an excess of low density lipoproteins, the cholesterol carried by them accumulates on the arterial wall, causing atherosclerosis over time. Serum LDL-C levels were significantly reduced five weeks after gavage M-J26P, H-J26P, J, atorvastatin, and b.longum BB536 compared to the HCD group. The in vivo high density lipoproteins are mainly responsible for transport of cholesterol from extrahepatic tissues to the liver where it is converted to bile acids or directly excreted from the gut via bile, thus preventing deposition of free cholesterol on extrahepatic tissue cells and serum HDL-C levels are markedly elevated in high fat high cholesterol diet mice following treatment with H-J26P, J and atorvastatin.
3.3 Biochemical index of mouse liver.
As shown in fig. 4, the liver is a major site of lipid metabolism and is easily affected by eating habits. Damaged hepatocytes release liver-specific enzymes, such as ALT and AST, resulting in elevated levels of both enzymes in the liver, consistent with the results of the HCD group in this study. After treatment, gavage J26P decreased TC, TG, LDL-C, AST and ALT levels in the liver of hypercholesterolemic mice and increased HDL-C levels consistent with previous serum biochemical results. The J26P can relieve liver lipid metabolism abnormality and restore liver function.
3.4 Total bile acid and total cholesterol content in mouse feces.
As shown in fig. 5, bile acids in feces are the main products of cholesterol metabolism. Thus, increased bile acid excretion in the feces may reduce serum cholesterol levels. This study showed that J26P intervention increased total cholesterol and total bile acid content in the feces of mice in the HCD group, suggesting that J26P may be directly eliminated by inducing cholesterol to convert to bile acid and then be partially excreted with the feces. This partly explains the reduction of liver fat deposition and the improvement of serum lipid status.
In summary, the effect of Lactobacillus plantarum J26 metameal on hypercholesterolemia mice was studied in this experiment. The result shows that the lactobacillus plantarum J26 metaplasia powder has good effect of improving the blood lipid and liver lipid metabolism disorder of a high cholesterol mouse, can improve liver injury and lipid accumulation, provides a certain pharmacological basis for the adjuvant therapy of hypercholesterolemia and related diseases, and provides a thinking for developing new products of the lactobacillus plantarum J26 metaplasia powder.
The foregoing is only a preferred embodiment of the invention, it being noted that: it will be apparent to those skilled in the art that various modifications and adaptations can be made without departing from the principles of the present invention, and such modifications and adaptations are intended to be comprehended within the scope of the invention.
Claims (9)
1. Lactobacillus plantarumLactobacillus plantarum) The application of the metapowder of J26 in preparing cholesterol-lowering medicines.
2. Use according to claim 1, characterized in that the metapowder is obtained by dry inactivation of lactobacillus plantarum J26.
3. Use according to claim 2, characterized in that the method of high-density fermentation before inactivation of lactobacillus plantarum J26 is: inoculating lactobacillus plantarum J26 strain into 4L skim milk powder culture medium with an inoculum size of 5%, and performing high-density fermentation for 18h, wherein the liquid fermentation environment is as follows: the temperature is 37 ℃, the humidity is 70%, the pH is 5.5, the aeration rate is 1.5vvm, the power of the stirrer is 1.5kwh +.m 3 The method comprises the steps of carrying out a first treatment on the surface of the The glucose concentration in the feed medium is 750g/L, the glucose concentration in the culture medium fed to the skim milk powder in 10h, 12h and 14h is 30g/L, the glucose concentration in the culture medium fed to the skim milk powder in 16h and 18h is 40g/L, and the viable count of the obtained fermentation liquor reaches 3.23 multiplied by 10 11 cfu/mL。
4. Use according to claim 3, characterized in that the fermentation broth obtained is subjected to spray drying under conditions of a needle passing frequency of 8Hz, a peristaltic speed of 5rmp, an air intake of 180 ℃, obtaining the metapowder of lactobacillus plantarum J26.
5. The post-production powder of Lactobacillus plantarum J26 obtained by the method according to claim 4, wherein the post-production powder comprises 24.89wt% of lipid and lipid molecules, 18.10wt% of organic acid and derivative, 12.85wt% of organic oxygen compound and the balance of Lactobacillus plantarum J26 inactivated thallus, wherein the concentration of the Lactobacillus plantarum J26 inactivated thallus is 10 8 Cells of Lactobacillus plantarum J26/g.
6. The post-cursor powder of lactobacillus plantarum J26 of claim 5, wherein the lipid and lipid molecules comprise one or more of ursolic acid, acetylcarnitine, D-panthenol, glycerophosphorylcholine, phosphatidylethanolamine, linolenic acid, linoleic acid, solamargine and capsaicin.
7. The metapowder of lactobacillus plantarum J26 according to claim 5, wherein the organic acid and derivative comprises one or more of 4-hydroxyisoleucine, arginine, fucosyllactose-N-hexasaccharide, pantothenic acid and anserine.
8. The metapowder of lactobacillus plantarum J26 according to claim 5, wherein the organic oxygen compound comprises one or more of 1, 4-d-xylobiose, 3.alpha.—galactobiose, 3.alpha.—mannobiose, 3' -sialyllactose, glucosamine sulfate, galactose-N-disaccharide, lactose, maltotetraose, melezitose and raffinose.
9. The use according to any one of claims 1 to 4, wherein the pharmaceutical dosage form comprises a granule, a capsule, a tablet, a pill or an oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310916587.XA CN116870038A (en) | 2023-07-25 | 2023-07-25 | Post-natal powder of lactobacillus plantarum J26 and application of post-natal powder in aspect of cholesterol reduction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310916587.XA CN116870038A (en) | 2023-07-25 | 2023-07-25 | Post-natal powder of lactobacillus plantarum J26 and application of post-natal powder in aspect of cholesterol reduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116870038A true CN116870038A (en) | 2023-10-13 |
Family
ID=88258472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310916587.XA Pending CN116870038A (en) | 2023-07-25 | 2023-07-25 | Post-natal powder of lactobacillus plantarum J26 and application of post-natal powder in aspect of cholesterol reduction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116870038A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117547029A (en) * | 2024-01-11 | 2024-02-13 | 东北农业大学 | Lactobacillus plantarum J26 metazoan freeze-dried powder with weight-losing and lipid-lowering effects, and preparation method and application thereof |
-
2023
- 2023-07-25 CN CN202310916587.XA patent/CN116870038A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117547029A (en) * | 2024-01-11 | 2024-02-13 | 东北农业大学 | Lactobacillus plantarum J26 metazoan freeze-dried powder with weight-losing and lipid-lowering effects, and preparation method and application thereof |
| CN117547029B (en) * | 2024-01-11 | 2024-04-05 | 东北农业大学 | Lactobacillus plantarum J26 metazoan freeze-dried powder with weight-losing and lipid-lowering effects, and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102481322A (en) | Bacterial compositions for prophylaxis and treatment of degenerative disease | |
| TWI634207B (en) | A lactobacillus plantarum, composition, culturing method and use of decrease uric acid, improvement of allergy and/or decrease blood sugar | |
| TWI636133B (en) | A lactobacillus plantarum, composition, culturing method and use of elimination of body fat, reduction of hepatomegaly and/or anti-inflammatory | |
| CN116870038A (en) | Post-natal powder of lactobacillus plantarum J26 and application of post-natal powder in aspect of cholesterol reduction | |
| CN116077536B (en) | Microecological live bacteria preparation for improving obesity-related metabolic diseases and preparation method and application thereof | |
| TWI636134B (en) | A lactobacillus plantarum, composition, culturing method and use of decrease blood lipids and/or decrease function index | |
| WO2020006663A1 (en) | Novel lactobacillus paracasei gks6 for mitigating metabolic syndrome, culture medium thereof, culture method, use, pharmaceutical composition, and edible composition | |
| CN106974262B (en) | Application of intestinal probiotic bacillus in treating and preventing obesity and related diseases | |
| CN115089619A (en) | Application of lactobacillus plantarum ZDY2013 in preparation with function of relieving non-alcoholic fatty liver disease | |
| CN110693916B (en) | Application of blautia in preparation of product for enhancing efficacy of hypolipidemic drug for treating hyperlipidemia | |
| CN110628668B (en) | Lactobacillus gasseri with function of preventing and treating hyperlipidemia, product composition, preparation method and application thereof | |
| CN113812634A (en) | Synbiotic composition and preparation method and application thereof | |
| KR101292714B1 (en) | Compositions and methods for prevention and treatment of obesity and obesity-related metabolic syndrome | |
| CN115369050A (en) | Klisteinella minutissima SJ-2 and application thereof | |
| CN101849969A (en) | Application of butyric acid producing beneficial bacterium in preparing preparation for preventing and treating severe disease gut barrier injury and post-injury complication | |
| WO2023237067A1 (en) | Use of akkermansia muciniphila in preparation of pharmaceutical composition or health care product composition for improving metabolic syndrome | |
| CN106834186B (en) | Lactobacillus plantarum microecological preparation and preparation method and application thereof | |
| WO2022089591A1 (en) | Application of glucosamine in preparation of non-alcoholic fatty treatment drugs | |
| CN108653298A (en) | Monosaccharide composition, pharmaceutical preparation and its application | |
| CN111714522B (en) | Bacteroides and application thereof | |
| CN110448569A (en) | A kind of composition with antidiarrheal efficacy and preparation method thereof and its application | |
| CN113215020B (en) | Roseburia MGB-2 and application thereof | |
| Sung-Won | Lactic acid bacteria increases hypolipidemic effect of crocin isolated from fructus of Gardenia jasminoides | |
| CN116836880B (en) | Fusobacterium praecox and application thereof | |
| Mojgani et al. | Invitro and Invivo Analysis of Human Milk Lactic Acid Bacteria Isolates for Their Anti-hypercholesterolemia Actions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |